A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris™ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis

NCT02273817 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

580

Enrollment

INDUSTRY

Sponsor class

Conditions

Seasonal Allergic Rhinitis

Interventions

DRUG: Ciclesonide nasal spray, 50 μg per actuation.

Sponsor

Apotex Inc.